Targeted Therapy for ER Positive Breast Cancer: 68 Real Stories

Stage IV HR-Positive Breast Cancer: Alison's Survivor Story

Patient Info: Alison, Female, Under 40 | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-positive

Metastatic Site: Cervical/neck lymph nodes

Alison reported complete remission since August 2017 while continuing intermittent maintenance chemotherapy, most recently 1 month of treatment followed by 2 months off.

The Patient StoryRead more →

Stage III HR-Positive Invasive Ductal Carcinoma: Stefanie's Survivor Story

Patient Info: Stefanie, Female | Stage III

Biomarkers: ER-positive, PR-positive and HER2-positive

Stefanie completed chemotherapy, breast-conserving surgery, prolonged Herceptin and 30 radiation treatments, then moved into survivorship while still adjusting to the lasting effects of treatment.

The Patient StoryRead more →

Stage IV HR-Positive Invasive Ductal Carcinoma: Shari's Patient Story

Patient Info: Shari S., Female | Stage IV

Biomarkers: ER-positive, PR-positive and HER2-positive; no inherited cancer mutation was identified

Metastatic Site: Brain; other initial metastatic sites were not named

Systemic imaging after chemotherapy showed no active disease, but brain metastases later required stereotactic radiation. Shari remained stage 4, continued Herceptin every 3 weeks and underwent brain MRI every 3–4 months.

The Patient StoryRead more →

Stable Stage IV breast cancer after a serious side effect from abemaciclib

Patient Info: Anonymized, Female | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-negative

Metastatic Site: bone marrow

About 2 years after starting treatment, she remained on reduced-dose abemaciclib without disease progression.

PubMed CentralRead more →

Stage III HER2-Positive Breast Cancer: Genoa's Survivor Story

Patient Info: Genoa M., Female | Stage III

Biomarkers: HER2-positive; ER-positive

As of June 2026, Genoa had completed treatment for Stage III HER2-positive, ER-positive breast cancer with neoadjuvant Taxotere/carboplatin/trastuzumab, lumpectomy, and radiation, and was focused on survivorship and rebuilding life after treatment.

The Patient StoryRead more →

Stage II HR-Positive Breast Cancer: Rach's Patient Story

Patient Info: Rach D., Female, Under 40 | Stage II

Biomarkers: ER-positive; PR-positive; HER2-positive

As of June 2026, Rach described Stage II triple-positive breast cancer treated with fertility preservation, 6 rounds of neoadjuvant TCHP including Herceptin, Zoladex ovarian suppression, and double mastectomy with reconstruction.

The Patient StoryRead more →

Metastatic invasive lobular breast cancer with stomach, ovarian, peritoneal, rectal, and jejunal spread

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: Primary tumor and gastric metastasis were ER/PR positive and HER2 negative; GATA3 supported breast origin in the metastasis.

Metastatic Site: stomach; ovaries; peritoneum; rectum; jejunum

During 2025, she remained under active oncologic management for metastatic invasive lobular breast cancer with gastrointestinal, ovarian, peritoneal, rectal, and jejunal involvement.

PubMed CentralRead more →

Invasive lobular breast cancer with colonic metastases treated with colectomy and capecitabine

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: Breast and colon metastatic samples were ER+ and HER2-; PR varied by sample

Metastatic Site: colon; perivisceral lymph nodes

After laparoscopic left colectomy and capecitabine for colonic metastases, follow-up showed no clinical or radiological evidence of recurrence or progression at 8 months postoperatively.

PubMed CentralRead more →

Stage II HR-Positive Invasive Ductal Carcinoma: Janet's Patient Story

Patient Info: Janet Ayala, Female, Under 40 | Stage II

Biomarkers: ER-positive; PR-positive; HER2-positive; ATM mutation

After complete pathologic response and completion of HER2-targeted infusions, Janet remained in survivorship-focused ongoing care with estrogen suppression and additional endocrine/targeted therapy planning to reduce recurrence risk.

City of HopeRead more →

Stage IIB breast cancer with severe radiation recall after abemaciclib

Patient Info: Anonymized, Female, 40s

Biomarkers: ER-positive; PR-positive; HER2 1+ / HER2-negative

The flap healed after abemaciclib was stopped and the tissue expander/patch were removed, but her long-term cancer-control and reconstruction outcomes were not yet reported.

PubMed CentralRead more →

Breast Cancer Discovered After Widespread Bone Metastases

Patient Info: Anonymized, female, 40s | Stage IV

Biomarkers: ER 90–95%; PR 90–95%; HER2 IHC 0; Ki-67 5%; germline BRCA1/2 negative

Metastatic Site: bone, bone marrow

She was receiving ongoing letrozole and ribociclib for Stage IV hormone receptor-positive, HER2-negative breast cancer with diffuse bone involvement.

PubMed CentralRead more →

Glycogen-rich clear cell breast carcinoma: HER2-positive early-stage case with disease-free follow-up

Patient Info: Anonymized, Female, 60s | Stage I

Biomarkers: ER-positive; HER2-positive; PR-negative; Ki-67 ~10%; intracytoplasmic glycogen confirmed

At 1-year follow-up, she had no evidence of breast cancer recurrence.

PubMed CentralRead more →

Stage IV ER/PR-positive breast cancer with retinal vein and artery occlusion during endocrine-targeted therapy

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: ER 70%; PR 100%; HER2-negative; Ki-67 10%

Metastatic Site: bone (cranial vault, right first rib, sternum, D5, D6,…

As of November 2025, she continued care for Stage IV ER/PR-positive breast cancer with bone metastases while also managing severe left-eye retinal vascular occlusion and limited visual recovery.

PubMed CentralRead more →

HER2-Positive Breast Cancer: Janella's Survivor Story

Patient Info: Janella Bustamante, Female, 40s

Biomarkers: Triple-positive: estrogen-, progesterone- and HER2-fueled breast cancer

As of October 2025, Janella had completed lumpectomy, chemotherapy, radiation and HER2-targeted biological therapy for triple-positive breast cancer and was on follow-up every 3 months; the source describes life after cancer but does not explicitly state NED/cancer-free.

Cleveland ClinicRead more →

Stage IIIC ER-positive male breast cancer: mastectomy, chemotherapy, radiation, tamoxifen and abemaciclib

Patient Info: Anonymized, Male, 40s | Stage III

Biomarkers: ER 90% positive; PR 60% positive; HER2 score 0; Ki-67 15%; BRCA1 and BRCA2 no pathogenic variants; CEA 2.4 ng/mL; CA15-3 13.6 U/mL

He remained on tamoxifen and dose-adjusted abemaciclib; annual follow-up imaging, including non-contrast CT, showed no local or distant relapse.

PubMed CentralRead more →

HER2-positive Stage IV breast cancer: T-DM1 extravasation wound healed after multidisciplinary care

Patient Info: Anonymized, Female, Under 40 | Stage IV

Biomarkers: ER 90% positive; PR 70% positive; HER2 IHC 3+

Metastatic Site: pelvis

As of October 2025, the T-DM1 extravasation wound had almost fully healed within about 4 weeks, and the patient continued adjuvant T-DM1 through a port; longer cancer-control status was not described.

PubMed CentralRead more →

ER/PR/HER2-positive breast cancer: gallbladder, liver, lung, pleural, and bone metastases after incomplete adjuvant therapy

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: Triple-positive breast cancer. Gallbladder metastasis kept ER/PR/HER2 positivity and Ki-67 >40%; markers supported breast origin.

Metastatic Site: gallbladder, liver, lung/pleura, bone

The patient died 3 years and 10 months after lumpectomy after metastatic ER/PR/HER2-positive breast cancer involved the gallbladder, liver, lungs/pleura, and bones following incomplete adjuvant therapy and loss to surveillance.

PubMed CentralRead more →

Metastatic hormone receptor-positive breast cancer: palbociclib and fulvestrant during dialysis

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: ER-positive; PR-negative; HER2 0 / HER2-negative; Ki-67 20.1%

Metastatic Site: lung, pleura, bone, right supraclavicular lymph node

As of August 2025, metastatic breast cancer had remained stable for 18 months on fulvestrant plus dialysis-adjusted palbociclib dosing, with hematologic toxicity managed through treatment interruptions, transfusion, and dose reduction.

PubMed CentralRead more →

Stage IIB HER2-positive apocrine breast carcinoma treated with chemotherapy, trastuzumab, radiation, and tamoxifen

Patient Info: Anonymized, Female, Under 40 | Stage II

Biomarkers: ER 80%; PR 5%; HER2-positive by HercepTest and FISH; Ki-67 15%; AR testing not performed

At 7 months of follow-up, the patient remained in remission, with no locoregional recurrence or distant metastasis reported.

PubMed CentralRead more →

HER2-positive node-positive breast cancer: mastectomy and adjuvant TCbHP

Patient Info: Anonymized, Female, Under 40 | Stage III

Biomarkers: HER2-positive breast cancer with ER/PR positivity, PD-L1 CPS 25

Adjuvant TCbHP was initiated after surgery, the first cycle was tolerated with supportive care, and regular monitoring was ongoing without evidence of distant recurrence or metastasis reported.

PubMed CentralRead more →

Isolated adrenal metastasis from breast cancer: adrenalectomy and exemestane plus palbociclib

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-negative; GATA3-positive; CK7-positive; mammaglobin-positive; GCDFP-15 rare staining

Metastatic Site: right adrenal gland

After laparoscopic right adrenalectomy for isolated metastatic breast carcinoma, follow-up CT abdomen/pelvis and PET-CT showed no metastatic disease elsewhere; surveillance while on exemestane and palbociclib showed no recurrence so far.

PubMed CentralRead more →

HER2-low lobular breast cancer with bone marrow involvement responding to T-DXd

Patient Info: Anonymized, Female | Stage IV

Biomarkers: Initial surgical specimen: ER-positive; PR-negative; HER2-negative. Bone marrow relapse: breast cancer infiltration with low HER2 staining.

Metastatic Site: bone marrow

Two years after starting T-DXd, this patient remained free of bone marrow disease and continued the same treatment regimen.

PubMed CentralRead more →

HER2-low lobular breast cancer with bone marrow involvement treated with T-DXd

Patient Info: Anonymized, Female | Stage IV

Biomarkers: Initial surgical specimen: ER-positive; PR-negative; HER2-negative. Bone marrow relapse: breast cancer infiltration with low HER2 staining.

Metastatic Site: bone marrow

Two years after starting T-DXd, this patient remained free of bone marrow disease and continued the same treatment regimen.

PubMed CentralRead more →

Metastatic male breast cancer: complete metabolic response after restarting anastrozole, leuprolide, abemaciclib, zoledronic acid, and radiation

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: ER >95%; PR >95%; HER2/neu-negative; Ki-67 30%; PIK3CA exon 21 pathogenic variant; BRCA1 not mutated; BRCA2 not mutated

Metastatic Site: bone (vertebral bodies T2-T6, L1, and L5)

As of May 2025, after restarting endocrine and targeted therapy and receiving palliative radiation, the last two PET scans showed complete metabolic response without disease progression, and brain MRI showed no metastasis.

PubMed CentralRead more →